Skip to main content

Table 3 Treatment-related adverse events (AEs) observed during the therapeutic Part

From: A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients

  Arm A - 370 MBq Arm B - 1110 MBq
N = 3 N = 5
Patients Patients
  N % N %
All treatment-related AEs 3 (100.0%) 4 (80.0%)
Lymphopenia 3 (100.0%) 4 (80.0%)
Anemia 3 (100.0%) 3 (60.0%)
Leucopenia 1 (33.3%) 4 (80.0%)
Asthenia 2 (66.7%) 2 (40.0%)
Hemoptysis 1 (33.3%) 3 (60.0%)
Thrombopenia 1 (33.3%) 3 (60.0%)
Neutropenia 0 (0.0%) 3 (60.0%)
Anorexia 2 (66.7%) 0 (0.0%)
Creatinine increased 0 (0.0%) 2 (40.0%)
Hypokalemia 1 (33.3%) 1 (20.0%)
Nausea 1 (33.3%) 1 (20.0%)
Hypoalbuminemia 1 (33.3%) 0 (0.0%)
Hypophosphatemia 0 (0.0%) 1 (20.0%)
Hypoxemia 0 (0.0%) 1 (20.0%)
Vomiting 1 (33.3%) 0 (0.0%)
Weight loss 1 (33.3%) 0 (0.0%)
All treatment-related AE ≥ Grade 3 1 (33.3%) 4 (80.0%)
Lymphopenia 0 (0.0%) 3 (60.0%)
Thrombopenia 1 (33.3%) 2 (40.0%)
Anemia 1 (33.3%) 1 (20.0%)
Neutropenia 0 (0.0%) 2 (40.0%)
Asthenia 1 (33.3%) 0 (0.0%)
Hemoptysis 0 (0.0%) 1 (20.0%)
Hypoxemia 0 (0.0%) 1 (20.0%)
Leucopenia 0 (0.0%) 1 (20.0%)